Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data

Vaccine

Volumn 30, Issue 33, 2012, Pages 5038-5058

  Gershman, Mark D ^a   Staples, J Erin ^a   Bentsi Enchill, Adwoa D ^b   Breugelmans, J Gabrielle ^c   Brito, Glacus S ^d   Camacho, Luiz Antonio Bastos ^e   Cottin, Pascale ^f   Domingo, Cristina ^g   Durbin, Anna ^h   Gascon, Joaquim ⁱ   Guenaneche, Fouzia ^j,t   Hayes, Edward B ⁱ   Jelenik, Zsuzsanna ^k   Khromava, Alena ^l   De Menezes Martins, Reinaldo ^m   Wilson, Mario Masana ^n,u   Massy, Nathalie ^o   Nasidi, Abdulsalami ^p   Niedrig, Matthias ^g   Sherwat, Adam ^q,v   Tsai, Theodore ^r   Vilella, Anna ⁱ   Wilson, Mary Elizabeth ^s   Kohl, Katrin S ^a   Blum, Mike ^t   Buttery, Jim ^t   Black, Steve ^t   Heath, Paul T ^t   Imoukhuede, Egeruan Babatunde ^t   Izurieta, Hector ^t   Khuri Bulos, Najwa ^t   Larson, Heidi ^t   Sturkenboom, Miriam ^t   Tomori, Oyewale ^t   Markoff, Lewis ^t   Bachtiar, Novilia S ^t   Banajeh, Salem ^t   Bravo, Lulu ^t   Chatterjee, Arani ^t   Cuevas Valdespino, Ivan Edelberto ^t   Excler, Jean Louis ^t   Falup Pecurariu, Cristian ^t   Fernandopulle, Rohini ^t   Gallegos, Karl ^t   Ghanaie, Roxana ^t   Hossain, Shah ^t   Huang, Wan Ting ^t   Humolli, Isme ^t   Klug, Bettina ^t   Kochhar, Sonali ^t   Kolie, Cece Vieux ^t   Kucuku, Merita ^t   Filipovic, Sanja Kurecic ^t   Lahariya, Chandrakant ^t   Nalin, David ^t   Navarro Alonso, Jose ^t   Nimmannitya, Suchitra ^t   Pagava, Karaman ^t   Pourmalek, Farshad ^t   Ramasamy, Ranjan ^t   Rouleau, Isabelle ^t   Dos Santos, Eliane Matos ^t   Santuccio, Carmela ^t   Schmidt, Claudia ^t   Seligman, Stephen J ^t   Sliman, Joseph ^t   Thorogood, Iris ^t   Trimis, Georgios ^t   Van Dinther, Kristy ^t   Varricchio, Frederick ^t   Wimalaratne, Omala ^t   Wong, Virginia ^t   Yameogo, Tene Marceline ^t   Zajdowicz, Thaddeus ^t   Zuber, Patrick ^t   Bonhoeffer, Jan ^t   Casagrande, Simone ^t   Faisst, Sabine ^t   Li, Yulin ^t   Sommerfeld, Norbert ^t   Weibel, Daniel ^t   Compingbutra, April ^t   Sommers, Theresa ^t   Monath, Thomas P ^t   Zaki, Sherif ^t   more..

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f Global Pharmacovigilance and Epidemiology   (France)

^g ROBERT KOCH INSTITUTE   (Germany)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j Sanofipasteur MSD   (France)

^k NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^l Sanofipasteur Ltd   (Canada)

^m Instituto de Technologia em Imunobiologicos   (Brazil)

ⁿ Ministry of Health   (Argentina)

^o ROUEN UNIVERSITY HOSPITAL   (France)

^p Federal Ministry of Health   (Nigeria)

^q NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^r Novartis Vaccines Cambridge   (United States)

^s HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^t Edificio Torre Barcelona ^*

^u PAN AMERICAN HEALTH ORGANIZATION   (Bolivia)

^v CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

Viscerotropic disease

Indexed keywords

VACCINE;

ARTICLE; HEALTH STATUS; HUMAN; IMMUNIZATION; INFORMATION PROCESSING; MULTIPLE ORGAN FAILURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SAFETY; STANDARDIZATION; TREATMENT RESPONSE; VISCEROTROPIC DISEASE;

EID: 84862775570     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.067     Document Type: Article

References (62)

1. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358(9276):121-122.
2. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358(9276):98-104.
3. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(9276):91-97.
4. Troillet N., Laurencet F. Effects of yellow fever vaccination. Lancet 2001, 358(9296):1908-1909.
5. Werfel U., Popp W. Effects of yellow fever vaccination. Lancet 2001, 358(9296):1909.
6. Adhiyaman V., Oke A., Cefai C. Effects of yellow fever vaccination. Lancet 2001, 358(9296):1907-1908.
7. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR 2002;51(44):989-93.
8. Centers for Disease Control and Prevention. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(RR-7):1-27.
9. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004, 132(5):939-946.
10. Gerasimon G., Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 2005, 98(6):653-656.
11. Doblas A., Domingo C., Bae H.G., Bohorquez C.L., de Ory F., Niedrig M., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 2006, 36(2):156-158.
12. Whittembury A., Ramirez G., Hernandez H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27(43):5974-5981.
13. Douce R.W., Freire D., Tello B., Vasquez G.A. A case of yellow fever vaccine-associated viscerotropic disease in Ecuador. Am J Trop Med Hyg 2010, 82(4):740-742.
14. Belsher J.L., Gay P., Brinton M., DellaValla J., Ridenour R., Lanciotti R., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25(50):8480-8485.
15. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23(25):3256-3263.
16. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26(48):6077-6082.
17. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004, 22(17-18):2103-2105.
18. Martins R.M., Maia M.L.S., Santos E.M., Cruz R.L.S., Santos P.R.G., Carvalho S.M.D., et al. Yellow fever post-marketing surveillance in Brazil. Procedia Vaccinol 2010, 2:178-183.
19. Barwick R. History of thymoma and yellow fever vaccination. Lancet 2004, 364(9438):936.
20. Monath T., Cetron M.S., Teuwen D.E. Yellow fever vaccine. Vaccines 2008, 959-1055. Saunders Elsevier, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
21. World Health Organization. Detection and investigation of serious adverse events following yellow fever vaccination: guidance from an informal consultation of experts, 18-19 November 2008, Geneva, Switzerland, 2010. Available on the world wide web: (last accessed March 23, 2012). http://whqlibdoc.who.int/hq/2010/WHO_HSE_GAR_ERI_2010.2_eng.pdf.
22. World Health Organization. Surveillance of adverse events following immunization against yellow fever: field guide for staff at the central, intermediate and peripheral level, 2010. Available on the world wide web: (last accessed March 23, 2012). http://whqlibdoc.who.int/hq/2010/WHO_HSE_GAR_ERI_2010.1_eng.pdf.
23. World Health Organization. Yellow fever surveillance and outbreak response: revision of case definitions, October 2010. Wkly Epidemiol Rec 2010;85(47):465-72.
24. Kohl K.S., Gidudu J., Bonhoeffer J., Braun M.M., Buettcher M., Chen R.T., et al. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 2007, 25(31):5671-5674.
25. Schrauder A., Henke-Gendo C., Seidemann K., Sasse M., Cario G., Moericke A., et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 2007, 369(9568):1232.
26. Ghaffar F., Carrick K., Rogers B.B., Margraf L.R., Krisher K., Ramilo O. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr Infect Dis 2000, 19(8):764-766.
27. Rasch D.K., Wells O., Fowlkes J. Fatal disseminated infection due to poliovirus type 2 vaccine. Am J Dis Child 1986, 140(12):1211-1212.
28. Jouanguy E., Altare F., Lamhamedi S., Revy P., Emile J.F., Newport M., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996, 335(26):1956-1961.
29. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
30. Monath T.P. Yellow fever: an update. Lancet Infect Dis 2001, 1(1):11-20.
31. Benichou C., Solal Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol 1991, 33(3):257-262.
32. Wise R.P., Bonhoeffer J., Beeler J., Donato H., Downie P., Matthews D., et al. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5717-5724.
33. Huerta-Alardin A.L., Varon J., Marik P.E. Bench-to-bedside review: rhabdomyolysis-an overview for clinicians. Crit Care 2005, 9(2):158-169.
34. Warren J.D., Blumbergs P.C., Thompson P.D. Rhabdomyolysis: a review. Muscle Nerve 2002, 25(3):332-347.
35. Bagley W.H., Yang H., Shah K.H. Rhabdomyolysis. Intern Emerg Med 2007, 2(3):210-218.
36. Sauret J.M., Marinides G., Wang G.K. Rhabdomyolysis. Am Fam Physician 2002, 65(5):907-912.
37. Craig S. Rhabdomyolysis in emergency medicine. eMedicine: updated September 21,2011. Available on the world wide web: (last accessed March 23, 2012). http://emedicine.medscape.com/article/827738-overview.
38. Muscal E. Morales de Guzman M. Pediatric rhabdomyolysis. eMedicne: updated April 27,2010. Available on the world wide web: (last accessed March 23, 2012). http://emedicine.medscape.com/article/1007814-diagnosis.
39. Pratt D.S., Kaplan M.M. Jaundice. Harrison's Principles of Internal Medicine 2008, 261-266. McGraw-Hill, New York, NY. 17th ed. A.S. Fauci, D.L. Kasper, D.L. Longo, E. Braunwald, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds.).
40. King C.H., Keating C.E., Muruka J.F., Ouma J.H., Houser H., Siongok T.K., et al. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. Am J Trop Med Hyg 1988, 39(4):361-368.
41. Traore M., Traore H.A., Kardorff R., Diarra A., Landoure A., Vester U., et al. The public health significance of urinary schistosomiasis as a cause of morbidity in two districts in Mali. Am J Trop Med Hyg 1998, 59(3):407-413.
42. Grossfeld G.D., Litwin M.S., Wolf J.S., Hricak H., Shuler C.L., Agerter D.C., et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology 2001, 57(4):599-603.
43. Mazza Nascimento M., Riella M.C. Raising awareness of chronic kidney disease in a Brazilian urban population. Braz J Med Biol Res 2009, 42(8):750-755.
44. Tsaras G., Owusu-Ansah A., Boateng F.O., Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am J Med 2009, 122(6):507-512.
45. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidelines for Clinical Safety Assesment (E2a-e). Available on the world wide web: (last accessed March 23, 2012). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
46. Council for International Organizations of Medical Sciences (CIOMS). Suspect adverse reaction report form. Available on the world wide web: (last accessed March 23,2012). http://www.cioms.ch/form/frame_form.htm.
47. The CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152(11):726-32. Available on the world wide web: (last accessed March 23, 2012). http://www.consort-statement.org/consort-statement/.
48. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999, 354(9193):1896-1900.
49. Des Jarlais D.C., Lyles C., Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004, 94(3):361-366.
50. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007, 147(8):573-577.
51. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
52. Reinhardt B., Jaspert R., Niedrig M., Kostner C., L'Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998, 56(2):159-167.
53. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002, 20(7-8):1004-1018.
54. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003, 188(8):1213-1230.
55. Wheelock E.F., Sibley W.A. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N Engl J Med 1965, 273:194-198.
56. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008, 198(4):500-507.
57. Roukens A.H., Soonawala D., Joosten S.A., de Visser A.W., Jiang X., Dirksen K., et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PloS One 2011, 6(12):e27753.
58. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006, 103(17):6694-6699.
59. Centers for Disease Control and Prevention. Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR 2010;59(5):130-2.
60. Traiber C., Coelho-Amaral P., Ritter V.R., Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J) 2011, 87(3):269-272.
61. Kuhn S., Twele-Montecinos L., MacDonald J., Webster P., Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 2011, 183(4):E243-E245.
62. Centers for Disease Control and Prevention. Transfusion-related transmission of yellow fever vaccine virus--California, 2009. MMWR 2010;59(2):34-7.